The pivot to FDA-approved generics as patents expire in various countries follows a year of soaring demand for the branded ...

Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.

Medicare drug plans don’t cover Saxenda because Medicare doesn’t cover GLP-1 agonists when prescribed for weight loss.

The FDA has approved the first generic GLP-1 specifically indicated for weight loss, according to a press release from Teva Pharmaceuticals. As Healio previously reported, Teva Pharmaceuticals ...

Tennis legend Serena Williams is sharing her journey with weight loss drugs, saying she's lost 31 pounds in 8 months using GLP-1s.

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

Advocates are pushing back against Tricare's plan to end its coverage of weight-loss drugs for Tricare for Life beneficiaries ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market.This approval and launch add to Teva's continu ...

GoodRx reports that HSA and FSA can cover weight-loss expenses if prescribed for medical conditions, requiring a letter of ...

"With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss," ...